RESUMEN
Expression of the calcitonin (CT)/calcitonin gene related peptide (CGRP) gene and the proopiomelanocortin (POMC) gene has been demonstrated by Northern blot hybridization analysis of RNA extracted from human medullary thyroid carcinoma (MTC), pheochromocytoma and lung carcinoma. CT mRNA in these tumors could not be distinguished in size from CT mRNA isolated from normal human thyroid tissue. CGRP mRNA (previously demonstrated in 12 out of 12 lung tumor cell lines investigated) could not be detected in 13 primary lung tumors or 10 metastases thereof. The length of POMC mRNA in MTCs (present in all 4 metastases investigated but not in 7 primary tumors) and pheochromocytomas is about 100 nucleotides more than pituitary POMC RNA. In lung tumors 2 POMC RNA species can be detected, one of the same size as in pituitary tissue and one about 100 nucleotides larger.
Asunto(s)
Neoplasias de las Glándulas Suprarrenales/genética , Calcitonina/genética , Neoplasias Pulmonares/genética , Proteínas del Tejido Nervioso/genética , Feocromocitoma/genética , Proopiomelanocortina/genética , ARN Mensajero/análisis , Neoplasias de la Tiroides/genética , Adenocarcinoma/genética , Péptido Relacionado con Gen de Calcitonina , Humanos , Hipófisis/análisis , Glándula Tiroides/análisisRESUMEN
A blocking ELISA was developed to distinguish between Aujeszky's disease virus (ADV)-infected and vaccinated pigs, on the basis of presence or absence of serum antibodies to glycoprotein I (gI) of ADV. The gI-ELISA detects antibodies that block the reaction of monoclonal antibodies to one or two epitopes on gI of ADV. The ADV-gI antibody response appeared between one and two weeks post-infection and persisted at a high level for at least seven months. Five of the nine ADV-vaccine strains examined were found to be "gI-negative". Pigs vaccinated with a gI-negative vaccine did not develop an ADV-gI antibody response until they were challenge-exposed to a virulent strain of ADV. The gI-ELISA is highly specific, sensitive and suitable for large-scale sero-epidemiological studies to identify infected pigs in populations vaccinated with gI-negative vaccines. The gI-ELISA provides, therefore, a basis for ADV-eradication programmes, which introduces a novel concept in the control of animal virus diseases.
Asunto(s)
Anticuerpos Antivirales/análisis , Ensayo de Inmunoadsorción Enzimática , Herpesvirus Suido 1/inmunología , Seudorrabia/diagnóstico , Enfermedades de los Porcinos/diagnóstico , Animales , Anticuerpos Antivirales/biosíntesis , Unión Competitiva , Seudorrabia/inmunología , Seudorrabia/prevención & control , Porcinos , Enfermedades de los Porcinos/inmunología , Enfermedades de los Porcinos/prevención & control , Proteínas del Envoltorio Viral/inmunología , Vacunas Virales/uso terapéuticoRESUMEN
A competitive enzyme immunoassay was developed to detect antibodies to a glycoprotein (gI) of Aujeszky's disease virus. Infected cell monolayers were used as antigen and a monoclonal antibody directed against an epitope of gI as indicator antibody. It was demonstrated that pigs vaccinated with the Bartha, BUK or NIA-4 strains did not produce antibody to the epitope of gI, whereas all wild-type viruses tested did induce this antibody. The antibody to the gI epitope persisted for at least 15 weeks. The present test, which enables us to distinguish pigs vaccinated with certain attenuated strains from pigs infected with wild-type Aujeszky's disease virus, may be of great value in future combined vaccination-eradication programmes for Aujeszky's disease.